Mobileye Global (NASDAQ: MBLY) sits at Layer 6 of the robotics value chain — mobile and autonomous-vehicle robotics. Its EyeQ chips sit behind the windshield of tens of millions of cars, powering automatic emergency braking, lane keeping and hands-free highway driving, and it shipped roughly 10 million units last quarter alone. In January 2026 it spent about $900 million buying Mentee Robotics, an Israeli humanoid-robot startup co-founded by Mobileye's own CEO. In July it announced it will build and operate its own robotaxi fleet.

Elena and Theo unpack a second quarter that beat on both revenue and earnings, raised full-year guidance — and still saw the stock fall 16.5% in a single session — its steepest drop since August 2024 — after founder Amnon Shashua announced he is stepping down as CEO after 27 years and the company guided third-quarter revenue down roughly 5-6% year over year. The bull case: real automotive-scale volume, $1.4 billion in cash, margin-rich upmarket design wins including Stellantis, a durable Israeli R&D incentive, and two option values the market is currently pricing near zero. The bear case: flat revenue, falling EyeQ average selling prices, gross margin down from 50% to 46%, Chinese competitors taking share on cost, a $3.79 billion non-cash goodwill impairment tied to Intel's 2017 acquisition, Intel still holding roughly 77% of the shares and 97% of the voting power, and post-earnings analyst targets ranging from $7 to $18.

We also give the honest verdict casual investors need: this is a robotics option, not a robotics thesis — humanoid and robotaxi revenue today is zero.

Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

This week on The Robot Investor: Washington escalates the robotics trade war. The FCC added new foreign-made humanoid robots, robot dogs, and power inverters to its "covered list," effectively banning new Chinese models from U.S. certification on national-security grounds. Morgan Stanley responded with a note calling out the sector's "PR problem" — even as the bank raised its 2026 China humanoid shipment forecast to 50,000 units and flagged the new ban itself as a cost headwind. Meanwhile Unitree Robotics formally launched its Shanghai Star Market IPO, aiming to raise 4.2 billion yuan at a 42-billion-yuan valuation — the sector's first real daily public stock price. BYD confirmed its first humanoid robot debuts in August at its retail showrooms, and Agility Robotics opened a new Silicon Valley Physical AI hub while making its Digit robot the first production humanoid to ship with Nvidia's new Halos safety system. Elena and Theo break down what a US import ban actually changes, why "PR problem" matters to investors, what Unitree's IPO numbers reveal, and why safety certification can be the real bottleneck between a working robot and a paying customer. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Kratos Defense & Security Solutions (NASDAQ: KTOS) sits at Layer 8 of the robotics stack — defense, drone, and aerospace robotics. It's the San Diego company behind the XQ-58A Valkyrie, a jet-powered "loyal wingman" drone that flies real missions alongside crewed fighter jets with no pilot onboard, alongside a satellite-ground-systems, propulsion, and hypersonics business. In this casual-investor deep dive, Elena and Theo unpack a stock that fell almost 10% in a single day on broad market fear (a hawkish Fed, spiking bond yields) and now sits roughly two-thirds below its January 52-week high of $134 — even as the underlying business posted 22.6% revenue growth last quarter, a record $14.3 billion bid pipeline, a growing backlog, and a wave of new contracts across hypersonics, counter-drone systems, and space. The bull case: real autonomous hardware flying real missions, a widening pipeline, Ark Invest buying in, and an average Wall Street price target more than double the current share price. The bear case: a trailing valuation running into the hundreds of times earnings, thin GAAP profit relative to an $8 billion-plus market cap, insider selling with no offsetting buys, one valuation model calling the stock significantly overvalued even after the crash, and stiff competition from private drone maker Anduril and defense giants General Atomics and Boeing. We ask what would have to be true for the thesis to work, and flag the August 4 earnings report as the next real test. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Rockwell Automation (NYSE: ROK) sits at Layer 5 of the robotics stack — full-stack industrial and warehouse automation. It's the century-old Milwaukee company behind the control systems that run modern factories, and, more recently, the Otto autonomous mobile robots now assembled on its own U.S. production line. In this casual-investor deep dive, Elena and Theo unpack why the stock is trading near an all-time high: a blowout fiscal Q2 (revenue up ~12%, adjusted EPS beating estimates by ~15%), five straight quarters of earnings beats, raised full-year guidance, a fresh $1 billion buyback on top of an existing one, and two real new growth stories — data centers (sales more than doubled year over year) and the Otto robotics line, which has logged over 10 million driving hours. The bear case is the price: a P/E near 47-50x versus an industry average in the mid-to-high 30s, real competitive pressure from Siemens and Schneider Electric on the software margins the bull case depends on, a wave of paused big-ticket automotive and food-and-beverage spending tied to trade-policy uncertainty, and a memory-chip cost headwind flagged for the current quarter. We also ask the honest question: is Rockwell a robotics stock, or an industrial giant with a robotics option quietly growing inside it? Our verdict — the robot is real, but it's the smaller sibling in a much bigger family — and the key date to watch is the August 4 earnings report. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

The robot week everyone waited for arrived — and Tesla's Optimus moment was an anticlimax. On this news episode of The Robot Investor, Elena and Theo break down Tesla's second-quarter earnings: revenue of 28.24 billion dollars (up 26 percent) beat estimates, but adjusted earnings of just 33 cents a share missed badly, the company posted a free-cash-flow deficit of about 1.09 billion dollars, reconfirmed capital spending above 25 billion, and the stock fell 14.5 percent to an eleven-month low near 319 dollars. The bigger tell for robotics investors: Tesla again disclosed no Optimus production count, and said the first units go to an internal "Optimus Academy" for training rather than to customers. We contrast that with rivals showing verifiable data — Agility's Digit robot has logged more than 65,000 operating hours across nine customer sites, and Figure's robots reportedly supported production of over 30,000 BMW vehicles. For the bear case, Morgan Stanley's new lead analyst Andrew Percoco downgraded Tesla and applied a 50 percent probability discount to Optimus's roughly 60-dollar-per-share value contribution. On the buyable side, Nvidia unveiled new Jetson Thor robot computers in Tokyo alongside Fanuc, Yaskawa, Kawasaki and Fujitsu, and London-based Humanoid became Europe's first pure-play humanoid unicorn with a 152-million-dollar Series A at a 1.35-billion-dollar valuation, backed by Bosch and Schaeffler. Plus, what to watch: Unitree's market debut and Cognex earnings on August 5.

Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Cognex (NASDAQ: CGNX) sits at Layer 1 of the robotics stack — perception and sensing. It's the machine-vision pioneer whose cameras and software let factories, warehouses and robots see, read barcodes, inspect for defects, and guide robot arms to the right part. In this casual-investor deep dive, Elena and Theo unpack why Cognex has been the best-performing major robotics stock of the last six months. The bull case is quality you rarely find in robotics: 24% revenue growth to $268 million last quarter, a seventh straight quarter of margin expansion, ~71% gross margins, $52 million of quarterly net profit, $622 million in cash with no debt, an ongoing buyback and dividend, two new AI vision platforms built with Nvidia and Qualcomm, and an activist investor pushing for even more. The bear case is the price: roughly 78 times earnings and 10.6 times sales — far above cousins Zebra and Rockwell — in a cyclical business whose own management has flagged a cloudier second half, plus tariff and China risk and customer concentration. We also answer the question every component investor should ask: is Cognex a robotics stock, or a profitable factory-vision company with a robotics tailwind? Our verdict — robotics is the option, the profitable vision business is the thesis — and the key date to watch is the August 5 earnings report. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Ambarella (AMBA): Edge AI Chips, The Robot's Brain | Jul 21, 2026

DESCRIPTION:

Ambarella (NASDAQ: AMBA) sits at Layer 2 of the robotics value chain — processing and edge compute. It designs low-power systems-on-a-chip that let a camera, a truck or a robot do its AI thinking on the device itself, right next to the sensor, instead of shipping video to a data centre and waiting for an answer. If lidar is the eyes, this is the reflexes.

Elena and Theo unpack a stock that has spent the year arguing with itself: up roughly 28% in a single day on June 30 after Rosenblatt Securities called it a "physical AI pure play" with a $120 target, down 8.9% on July 15, and trading near $62 in late July against a 52-week range of about $48 to $97.

The bull case: record fiscal 2026 revenue of about $391 million with edge AI now roughly 80% of the business; a record automotive quarter driven by commercial-vehicle telematics; and a long-term agreement with Hanwha Group estimated at over $800 million in potential revenue across more than ten years, spanning video security, robotics, industrial automation and life sciences.

The bear case: a GAAP net loss of $18.1 million on $100.4 million of Q1 revenue, roughly $69.6 million of losses across the trailing twelve months, five years of losses growing about 17.5% a year, slipping gross margins, customer and distributor concentration, and competitors named Nvidia and Qualcomm.

And the honest question for any component investor: with more than 15 robotics design wins worth over $100 million in lifetime revenue against $405 million of annual revenue, is robotics the thesis here — or a free option stapled to a security-camera chip business? We give the deflating answer.

Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Last week one humanoid robot maker got cleared to go public. This week it became a stampede. On The Robot Investor, analyst Elena Vance and curious investor Theo Brooks break down a red-hot week for robotics stocks. China's humanoid startups are racing each other to the public markets: LimX Dynamics raised $200 million in a pre-IPO round at a ~15 billion yuan ($2.2 billion) valuation with its founder declaring "listing is a must," Galbot picked CITIC, Huatai and UBS for a Hong Kong IPO, and roughly 20 Chinese embodied-AI startups now carry valuations above 10 billion yuan. Meanwhile Unitree's approved Shanghai STAR Market IPO is drawing grey-market chatter above 100 billion yuan (~$14.7 billion) — more than double its own ~42 billion yuan prospectus floor — even though its Q1 2026 profit fell over 50%. We contrast all that pre-revenue excitement with a robotics stock you can actually buy: Intuitive Surgical (ISRG) beat Q2 2026 earnings with revenue up 19% to $2.89 billion, ~16% procedure growth, 468 da Vinci systems placed, and non-GAAP EPS of $2.80. We explain the razor-and-blades model, weigh roboticist Rodney Brooks' "pure fantasy thinking" bubble warning, preview Tesla's July 23 Optimus update, and dig into why rare-earth magnets (and Zhenghai Magnetic's heavy-rare-earth-free push) quietly decide who wins. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

PROCEPT BioRobotics (NASDAQ: PRCT) is a Layer 7 surgical-robotics pure-play whose AQUABEAM and HYDROS robots deliver "Aquablation therapy" — a heat-free, robotically guided waterjet that removes excess prostate tissue to treat an enlarged prostate (BPH), a condition PROCEPT says affects roughly 40 million U.S. men. In this casual-investor deep dive, Elena and Theo explain where PROCEPT sits in the robotics value chain and why it's a genuine robotics business rather than a sticker on a box: the razor-and-blades model of a ~$485,000 robot plus a ~$3,500 single-use handpiece per procedure, a U.S. install base up 40% to 765 systems, and procedures up ~30%. Then they dig into the puzzle of the week — a company posting 20% revenue growth, strong FDA news, and fresh analyst coverage whose stock still hit a 52-week low near $19. The bull case: 27–33% guided revenue growth, a huge underpenetrated market, and a new prostate-CANCER expansion option via the WATER IV RP and WATER IV AS trials. The bear case: a widening net loss (~$31.6M in Q1 2026, ~$102M trailing-twelve-month), a full-year loss guided to roughly $79–92M, real competition from Teleflex's UroLift, Boston Scientific's Rezūm, and prostate artery embolization, and a batch of recent downgrades (BofA to $20, Truist to Hold/$25). We close with what a casual investor should watch: the July 30 earnings report, U.S. procedure growth, the cash balance, and analyst sentiment. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

Aurora Innovation (NASDAQ: AUR) is one of the purest ways a regular investor can bet on autonomous-vehicle robotics — Layer 6 of the robotics stack. This deep dive explains, in plain English, what Aurora actually does: it doesn't build trucks, it builds the "Aurora Driver," an SAE Level 4 self-driving system installed on trucks from partners like PACCAR and Volvo and sold to carriers as a per-mile subscription — "Driver as a Service." Aurora already runs genuinely driverless commercial freight on Texas highways and is expanding its lanes. The bull case is strong: a near-trillion-dollar trucking market with a chronic driver shortage, first-mover driverless revenue, blue-chip customers including McLane (a Berkshire Hathaway subsidiary), an independent safety-case validation by Edge Case, a Continental partnership to mass-produce hardware from 2027, and roughly $1.3 billion in liquidity. But the bear case is unusually heavy: Aurora booked only about $1 million of revenue last quarter against a roughly $9 billion market cap, lost around $223 million in that same quarter, burned about $159 million of cash, and grew its share count roughly 18% in a year — with more dilution likely, since analysts don't expect positive free cash flow until 2028. We walk through what would have to be true for the thesis to work and what a casual investor should watch, starting with the July 29, 2026 Q2 report. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.